• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Ionis Pharmaceuticals (NQ: IONS )

    47.66 -0.30 (-0.64%)
    Streaming Delayed Price Updated: 12:42 PM EDT, Jul 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 380,851
    Open 48.06
    Bid (Size) 47.60 (4)
    Ask (Size) 47.71 (4)
    Prev. Close 47.96
    Today's Range 47.05 - 48.82
    52wk Range 35.95 - 54.44
    Shares Outstanding 141,797,854
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Assessing Ionis Pharmaceuticals: Insights From 6 Financial Analysts
    Via Benzinga

    Performance

    YTD
    -9.86%
    -9.86%
    1 Month
    +16.92%
    +16.92%
    3 Month
    +16.49%
    +16.49%
    6 Month
    -7.09%
    -7.09%
    1 Year
    +13.25%
    +13.25%

    More News

    Read More
    RXO, Alnylam Pharmaceuticals And Other Big Stocks Moving Lower In Monday's Pre-Market Session
    Via Benzinga
    Masters In Trading - Saturday, June 22
    Via Talk Markets
    Deep Dive Into Ionis Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
    Via Benzinga
    Ionis Pharmaceuticals Reveals Late-Stage Donidalorsen Data, Analyst Says Results Show Competitive Hereditary Angioedema Profile
    Via Benzinga
    Exposures Product Safety
    The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
    Via Benzinga
    The Latest Analyst Ratings For Ionis Pharmaceuticals
    Via Benzinga
    Cracking The Code: Understanding Analyst Reviews For Ionis Pharmaceuticals
    Via Benzinga
    Europe Approves Biogen's Tofersen For Adult Patients With Rare Type Of Neurodegenerative Disorder
    Via Benzinga
    Tale Of Two Ionis-Partnered Neurology-Focused Early Stage Assets-Biogen Discontinues One, Decides Not To Exercise Licensing Option For Another
    Via Benzinga
    Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
    From Biogen Inc.
    Via GlobeNewswire
    The 3 Most Undervalued Pharma Stocks to Buy in May 2024
    Via InvestorPlace
    Earnings Scheduled For February 21, 2024
    Via Benzinga
    Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 8 Analysts
    Via Benzinga
    IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    Genetic Medicines Focused-Ionis Pharmaceuticals' Fatty Liver Candidate Lowers Excess Liver Fat, Midstage Study Data Shows
    Via Benzinga
    Are These 5 Undervalued Stocks Ready to Break Out?
    Via MarketBeat
    New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
    From Biogen Inc.
    Via GlobeNewswire
    JP Morgan Maintains Neutral Rating for Ionis Pharmaceuticals: Here's What You Need To Know
    Via Benzinga
    Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
    Via Benzinga
    Exposures Product Safety
    Rare Disease Focused Ionis Pharmaceuticals Gears Up for FDA Submission After Donidalorsen Outperforms Placebo In Swollen Vessels Study
    Via Benzinga
    Exposures Product Safety
    Praxis Precision Medicines Provides Update on Advancing Clinical Stage Portfolio
    From Praxis Precision Medicines, Inc.
    Via GlobeNewswire
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Via Investor's Business Daily
    2024 And Beyond – Exploring Six Investment Megatrends With Tema ETFs
    Via Benzinga
    Topics ETFs
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.